News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
27-Aug-2007 - Chief Commercial Officer (CCO) Peter Nordkild has resigned his position in Pharmexa to accept the position as CEO in the Danish biotech company Egalet. Peter Nordkild's responsibilities will until further notice be taken over by Chief Executive Officer Jakob Schmidt.
25-Jun-2007 - Pharmexa-Epimmune, the U.S.-based subsidiary of Pharmexa A/S, presented selected data from its influenza vaccine program at the Influenza Conference entitled, "Options for the Control of Influenza VI," held in Toronto, Ontario, Canada. The company's "universal" vaccine strategy combines the use ...
07-May-2007 - The FDA has approved Pharmexas IND to start the PrimoVax trial in the United States. PrimoVax is a pivotal phase III trial testing the peptide vaccine GV1001 in patients with non-resectable pancreatic cancer. According to the plan the trial will enrol a total of 520 patients with pancreatic ...
03-May-2007 - Pharmexa-Epimmune and Bavarian Nordic announced the initiation of a Phase I trial testing two HIV vaccines EP1233 and MVA-BN Polytope in combination. The clinical trial will be conducted by the HIV Vaccine Trials Network (HVTN) which is supported through a cooperative agreement with the National ...
04-Apr-2007 - Pharmexa and Affitech A/S have entered into a license agreement to promote a single chain bi-specific antibody (diabody) technology to third parties for further product development, as well as to utilize the technology for Affitech's own research. Pharmexa has granted a worldwide exclusive ...
19-Mar-2007 - A Phase III trial testing a new treatment for pancreatic cancer has now been initiated. Pharmexa has developed the drug and is co-financing the trial together with pharmaceuticals company Roche and Cancer Research UK. Referred to as the TeloVac trial, the recently initiated Phase III trial is a ...
20-Dec-2006 - Pharmexa-Epimmune, a subsidiary of Pharmexa A/S, and Ichor Medical Systems have entered into a collaborative agreement and have agreed to licensing terms for Pharmexa's HER-2 DNA AutoVacTM. This is the second time Pharmexa agrees to grant a non-exclusive license to the HER-2 DNA AutoVacTM ...
29-Nov-2006 - The first patient has been treated in the HeptoVax phase II trial of GV1001 in liver cancer, following receipt of the required approvals in France, Spain and Germany. The HeptoVax trial is a phase II trial evaluating the safety and efficacy of GV1001 in advanced hepatocellular carcinoma ("HCC" or ...
15-Sep-2006 - Karen Lykke Sørensen, General Manager for Sanofi-Aventis in Denmark and Ole Steen Andersen, Executive Vice President and CFO in Danfoss A/S, will - upon being elected at the next general assembly in Pharmexa - join Pharmexa's board of directors. Karen Lykke Sørensen has more than 12 years ...
12-Sep-2006 - Pharmexa has been granted a patent in the United States and has received communication of intent to grant from the European patent authorities on GV1003, a new peptide vaccine candidate aimed at the telomerase enzyme which is crucial to cancer cells' ability to divide. The telomerase enzyme, ...
© 1997-2024 LUMITOS AG, All rights reserved